BRCA 1 mutation, leptin and estrogen levels in breast cancer patients

Pre- and postmenopausal patients with breast cancer were screened for mutation of the BRCAI gene and estrogens and leptin levels were measured. In postmenopausal BRCA1 mutation carriers, leptin levels were significantly lower and correlated with the body mass index (BMI). No significant difference in leptin levels was revealed between pre- and postmenopausal patients. Our findings suggest the existence of an alternative mechanism responsible for carcinogenesis in breast cancer patients with a genetic background.

Leptin, BRCA I mutation, Breast cancer

[1] Gorski B., Jakubowska A., Huzarski T., Byrski T., Gronwald J., Grzybowska E. et al.: "A high proportion of founder BRCA l mutations in Polish breast cancer families". Int. J. Cancer, 2004, 110, 683.

[2] Gorski B., Byrski T., Huzarski T., Jakubowska A., Menkiszak J., Gronwald J. et al.: "Founder mutations in the BRCAl gene in Polish families with breast-ovarian cancer". Am. J. Hum. Genet., 2000, 66, 1963.

[3] Ford D., Aston D.F., Bishop D.T., Narod S.A., Goldgar D.E.: "Risk of cancer in BRCAl mutation carriers. Breast cancer linkage consortium". Lancet, 1994, 343, 692.

[4] Stephenson G.D., Rose D.P.: "Breast cancer and obesity. An update". Nutrit. Cancer, 2003, 45, 1.

[5] Daling J.R., Malone K.E., Doody D.R., Johnson L.G., Gralow J.R., Porter P.L.: "Relation of body mass index to tumor markers and surviva! among young women with invasive ductal breast carcinoma". Cancer, 2001, 92, 720.

[6] Marcus J.N., Watson P., Page D.L., Narod S.A., Tonin P., Lenoir G.M. et al.: "Hereditary breast cancer: pathology, prognosis and BRCAl and BRCA2 gene linkage". Cancer, 1996, 77, 697.

[7] Ozet A., Arpaci F., Yilmaz M.I., Ayta H., Ozturk B., Komurcu S. et al.: "Effects of tamoxifen on the serum leptin level in patients with breast cancer". Jpn. J. Clin. Oneal., 2001, 31, 424.

[8] Coskun U., Gunel N., Toruner F.B., Sancak B., Onuk E., Bayram O et al.: "Serum leptin, prolactin and vascular endothelial growth factor (V EGF) levels in patients with breast cancer". Neoplasma, 2003, 50, 41.

[9] Petridou E., Papadiamantis Y., Marcopoulos C., Spanos E., Dessypris N., Trichopoulos D.: "Leptin and insulin growth factor I in relation to breast cancer (Greece)". Cancer Causes Control, 2000, 11, 383.

[10] Catalano S., Mauro L., Marsico S., Giordano C., Rizza P., Pago V et al.: "Leptin induces, via ERK1/ERK2 signal, functional activation of estrogen receptor alpha in MCF-7 cells". J. Biol. Chem., 2004, 279, 19908.

[11] Rebbeck T.R., Lynch H.T., Neuhausen S.L., Narod S.A., Van't Veer L., Gaber S.E. et al.: "Prophylactic oophorectomy in carriers of BRCAl or BRCA2 mutations". N. Engl. J. Med., 2002, 346, 1616.

[12] Takekoshi K., Ishi K., Nanmoku T., Schibuyas S., Kawakami Y., Isobe K. et al.: "Leptin stimulates catecholamine synthesis in a PKC-dependent manner in cultured porcine adrenal medullary chromaffin cells". Endocrinology, 2001, 142, 4861.